Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14506550 | 0.86 | ALDH1A1 (0.42) | MAPTMEN1KMT2A | |
| SCHEMBL3008401 | 0.85 | GHSR (0.38) | PTGDR2AKR1B1MAPTMEN1KMT2A | |
| SCHEMBL3008230 | 0.84 | PTGDR2 (0.41) | PTGDR2AKR1B1 | |
| SCHEMBL3012384 | 0.81 | MEN1 (0.35) | PTGDR2MEN1KMT2A | |
| SCHEMBL281912 | 0.80 | — | — | |
| SCHEMBL3010580 | 0.79 | PTGDR2 (0.33) | PTGDR2MEN1KMT2A | |
| SCHEMBL280856 | 0.73 | SCN9A (0.50) | PTGDR2MEN1KMT2A | |
| SCHEMBL2995274 | 0.73 | ALDH1A1 (0.43) | PTGDR2MAPT | |
| SCHEMBL14506547 | 0.71 | ALDH1A1 (0.49) | MAPTMEN1KMT2A | |
| SCHEMBL14506568 | 0.71 | ALDH1A1 (0.51) | MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241834-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2017-11-08 | — | — | EP | disclosed |
| EP-2428515-B9 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2014-09-17 | — | — | EP | disclosed |
| EP-2752417-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2014-07-09 | — | — | EP | disclosed |
| EP-2428515-B1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2014-05-07 | — | — | EP | disclosed |
| US-8466188-B2 | Use of spiro-oxindole compounds as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-20120122909-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-20100173967-A1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | US | disclosed |
| US-20100130487-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-27 | — | — | US | disclosed |
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-20 | — | — | US | disclosed |
| EP-2073806-A2 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008060789-A2 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | PTGDR2 190/4885AKR1B1 112/4885MAPT 447/4885 |
| US-20100130487-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | PTGDR2 190/4885AKR1B1 112/4885MAPT 447/4885 |
| US-20120122909-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | PTGDR2 190/4885AKR1B1 112/4885MAPT 447/4885 |
| US-20100173967-A1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | KLK3, REN, AVPR1B | PTGDR2 364/4885AKR1B1 9/4885MAPT 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.